User login
Language
Anonymous's groups in this site
User is not a member of any group.
Your groups across all your sites
User is not a member of any group.
Recent Content
Recent Comments
- Update: Biden announced vaccine doses and cash for Africa 1 month 2 weeks ago
- Florida's new COVID booster guidance called misinformation 1 month 2 weeks ago
- WHO's authorization of mpox vaccine should ease global access 1 month 3 weeks ago
- Ten symptoms of long COVID in children 2 months 1 week ago
Who's online
There are currently 0 users online.
You are here
AFP Feb. 23, 2015
Los Angeles - Early results from an Ebola trial using the experimental drug Avigan (favipiravir) showed Monday it was somewhat effective at saving lives if given early in the illness, but not later.
Early results from an Ebola trial using the experimental drug Avigan (favipiravir) show it is somewhat effective at saving lives if given early in the illness (AFP Photo/George Frey)
The antiviral treatment is being developed by the Japanese company Toyama Chemical, and has been shown safe and effective against some other viruses including influenza, West Nile and yellow fever.
An ongoing clinical trial in Guinea is testing the drug's use in patients with the Ebola virus, which causes severe vomiting, diarrhea and sometimes fatal bleeding.
Results from only 80 people are available so far, but they show that among those who received the drug early in their illness, 15 percent died of Ebola.
Read complete story.
Comments
Ebola drug in Guinea helps some, stirs debate on broader use
REUTERS by Emma Farge Feb. 23, 2015
DAKAR ---
..."We think this is a sufficiently encouraging sign for it to be made available to Ebola patients more widely," said Augustin Augier, secretary general of ALIMA, which runs the treatment center in Nzerekore, in southeast Guinea.
Several health officials said the drug should be given in Sierra Leone, where more than 160 patients are suspected of carrying the virus....
"We think this is a sufficiently encouraging sign for it to be made available to Ebola patients more widely," said Augustin Augier, secretary general of ALIMA, which runs the treatment center in Nzerekore, in southeast Guinea.
But the World Health Organization (WHO) said more research should be done. "There are not sufficient data to draw firm conclusions about this drug's efficacy against Ebola," a spokeswoman said.
Asked whether the WHO would facilitate the use of favipiravir more widely, she said: "It is up to national regulatory authorities how and whether to use it."
Read complete story.
http://www.reuters.com/article/2015/02/23/us-health-ebola-drug-idUSKBN0LR27G20150223